Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation
Authors:
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in Rheumatic Disease Clinics of North America
- Vol. 29 (3) , 463-479
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The cutting edge of spondylarthropathy research in the millenniumArthritis & Rheumatism, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative studyArthritis & Rheumatism, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- Sulfasalazine in the treatment of spondylarthropathyArthritis & Rheumatism, 1995
- Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis & Rheumatism, 1995
- SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITYRheumatology, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Seronegative polyarthritis. a unified conceptArthritis & Rheumatism, 1978